Chunna Jin | Heart Failure | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Dr. Chunna Jin | Heart Failure | Best Researcher Award

Dr. Chunna Jin is the Associate Chief Physician at the Department of Cardiovascular Medicine, The Second Affiliated Hospital of Zhejiang University, China. She holds a Ph.D. in Cardiovascular Medicine from The Chinese University of Hong Kong and completed her postdoctoral fellowship at St. Francis Hospital, New York, USA. With a strong focus on ischemic heart disease, heart failure, and cardiovascular imaging, Dr. Jin combines advanced clinical expertise with cutting-edge research. She has published extensively in high-impact journals and is recognized for her international collaborations and contributions to innovative, patient-centered cardiovascular care.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Dr. Chunna Jin embarked on her academic journey with a profound interest in cardiovascular health. Her early dedication to medicine led her to pursue advanced studies in one of Asia’s top medical institutions. She earned her Ph.D. in Cardiovascular Medicine from the Faculty of Medicine, The Chinese University of Hong Kong (CUHK), where she laid the foundation for her clinical expertise and scientific research. This phase of her education not only enriched her clinical understanding but also honed her analytical skills, preparing her for a dynamic career in medicine.

🏥 PROFESSIONAL ENDEAVORS:

Currently, Dr. Jin serves as an Associate Chief Physician at the Department of Cardiovascular Medicine, The Second Affiliated Hospital of Zhejiang University (ZUCC) in China. In this pivotal role, she combines her clinical acumen with innovative medical practices to deliver high-quality cardiovascular care. Her career also includes international exposure as a Postdoctoral Research Fellow at St. Francis Hospital in New York, USA, a renowned center for cardiovascular treatment and research. This experience broadened her global perspective and deepened her understanding of diverse healthcare systems.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON HEART FAILURE:

Dr. Jin’s research is focused on cardiovascular diseases, with a particular interest in ischemic heart conditions, heart failure, and minimally invasive interventions. She has contributed extensively to studies involving cardiovascular pharmacotherapy, echocardiographic techniques, and electrophysiological diagnostics. Her interdisciplinary approach integrates clinical trials, translational medicine, and patient-centered innovations, contributing to a deeper understanding of heart health at both cellular and systemic levels.

🌍 IMPACT AND INFLUENCE:

Through her work, Dr. Jin has significantly influenced both clinical practice and academic research in cardiovascular medicine. Her international collaborations and her leadership at ZUCC have helped introduce cutting-edge diagnostic and therapeutic protocols into clinical settings. She is regarded as a mentor and guide by younger professionals in the field, and she has played a vital role in enhancing healthcare standards through training and development initiatives.

📚 ACADEMIC CITES AND PUBLICATIONS:

Dr. Jin has authored and co-authored numerous peer-reviewed journal articles, case reports, and conference papers, many of which are frequently cited in cardiovascular research. Her work appears in leading journals such as the European Heart Journal, Journal of the American College of Cardiology (JACC), and Circulation. These contributions have not only gained academic recognition but also have direct clinical applications that benefit patients worldwide.

🏅 LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Chunna Jin’s legacy is defined by her dedication to clinical excellence, innovative research, and global collaboration. Moving forward, she aims to pioneer personalized treatment models for cardiovascular patients, integrating genomic data and AI-driven diagnostics into mainstream medicine. Her vision includes fostering international research networks, enhancing telecardiology, and contributing to global health policy on cardiovascular disease prevention.

⭐CONCLUSION:

Dr. Chunna Jin is a trailblazing leader in cardiovascular medicine whose dedication to clinical excellence and research innovation continues to make a global impact. Her journey from prestigious academic institutions to influential hospital roles reflects her unwavering commitment to improving heart health. With a passion for mentoring, international collaboration, and advancing medical science, Dr. Jin stands as a role model for future healthcare professionals. Her ongoing efforts in precision medicine and digital healthcare promise a brighter, healthier future for cardiovascular patients worldwide. Dr. Jin’s legacy is one of compassion, expertise, and visionary progress.

TOP NOTABLE PUBLICATIONS

Association between Glycated Albumin and Adverse Outcomes in Patients with Heart Failure

  • Authors: Senmiao Chen, Guanzhong Chen, Yu Jin, Shiyu Zhu, Liangliang Jia, Chengchen Zhao, Chunna Jin, Meixiang Xiang

  • Journal: Journal of Diabetes Investigation

  • Year: 2024

First-Phase Ejection Fraction to Predict Adverse Outcomes in Patients with Heart Failure

  • Authors: Chunna Jin, Guanzhong Chen, Senmiao Chen, Hong Ma, Meixiang Xiang

  • Journal: International Journal of Cardiology

  • Year: 2024

Ruping Dai | Cardiovascular Anesthesia | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Prof. Dr. Ruping Dai | Cardiovascular Anesthesia | Best Researcher Award 

Prof. Dr.  Ruping Dai, Second Xiangya Hospital, China

Prof. Dr. Ruping Dai is the Director of Anesthesiology at the Second Xiangya Hospital, Central South University, China. He earned his Ph.D. in Clinical Medicine from the National University of Singapore in 2004 and completed postdoctoral research at the Institute of Molecular and Cell Biology, Singapore. Prof. Dai specializes in clinical anesthesia, pain management, intensive care, perioperative medicine, and organ protection. He has led four projects funded by the National Natural Science Foundation of China and has published 24 SCI papers. His accolades include the New Century Talent Support Program (2012) and the Hunan Province Outstanding Youth Fund (2013).

AUTHOR PROFILE

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Dr. Ruping Dai embarked on his academic journey at the Xiangya School of Medicine, Central South University, where he earned his Bachelor’s degree in Anesthesiology (1993-1998). His thirst for knowledge led him to pursue a Ph.D. in Medicine at the National University of Singapore (2000-2004), where he focused on advanced medical research. He further honed his expertise as a Postdoctoral Fellow at the National Institute of Molecular and Cell Biology, Singapore (2004-2006), gaining in-depth knowledge in molecular and cellular biology applications in anesthesiology.

🏥PROFESSIONAL ENDEAVORS:

Dr. Dai began his career in the Department of Cardiothoracic Surgery, Union Hospital Affiliated to Fujian Medical University (1998-2000), specializing in cardiovascular anesthesia and intensive care. Since October 2006, he has been a Chief Physician and Doctoral Supervisor at the Department of Anesthesiology, Second Xiangya Hospital, Central South University. Over the years, he has played a vital role in clinical anesthesia and Anesthesia Intensive Care Units (AICU), ensuring excellence in patient care and medical education.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR ANESTHESIA:

Dr. Dai’s research primarily focuses on anesthesiology, organ protection, perioperative care, and immunosuppression mechanisms in sepsis. He has led multiple groundbreaking studies on topics such as:

  • Postoperative sepsis mechanisms
  • Perioperative acute lung injury
  • Neuroplasticity and postoperative cognitive dysfunction (POCD)
  • Microglial/macrophage polarization in spinal cord ischemia-reperfusion injury

Dr. Dai has hosted 7 National Natural Science Foundation (NSFC) projects, receiving significant research funding, including:

  • Key Project on Hematogenous Macrophage Role in Postoperative Sepsis (2025-2028) – RMB 2.6 million
  • SIRT5-Mitochondrial Metabolic Axis in Perioperative Acute Lung Injury (2024-2027) – RMB 490,000
  • Macrophage Dysfunction in Sepsis Immunosuppression (2021-2024) – RMB 560,000
  • Microglia Polarization in Spinal Cord Ischemia-Reperfusion Injury (2018-2021) – RMB 540,000

🌍IMPACT AND INFLUENCE:

Dr. Dai holds several prestigious administrative positions, including:

  • Director of Anesthesiology, Second Xiangya Hospital, Central South University
  • Director, Institute of Anesthesiology, Central South University
  • Director, Hunan Anesthesia Clinical Medicine Research Center
  • Director, Hunan Provincial Organ Damage Prevention and Treatment Engineering Center

In academia, he serves as:

  • Deputy Chairman, Hunan Provincial Anesthesiology Committee
  • National Committee Member, Anesthesiology Branch, Chinese Medical Doctor Association
  • Vice Chairman, 13th Youth Committee of the Chinese Medical Association Anesthesiology Branch
  • Deputy Director, Orthopedics Group, Chinese Medical Association Anesthesiology Branch
  • Standing Committee Member, Cardiovascular Anesthesia Branch, Chinese Society of Thoracic and Cardiovascular Anesthesiology

📖ACADEMIC CITES AND SCHOLARLY CONTRIBUTIONS:

Dr. Dai has played a crucial role in education, having authored and co-edited several key textbooks:

  1. Clinical Anesthesiology (First Editor, Science Press, 14th Five-Year Plan)
  2. Postgraduate Textbook: Anesthesiology (Selected Topics of Basic Anesthesia Research, People’s Medical Publishing House, 2014)
  3. Resident Medical Planning Textbook: Anesthesiology (Postoperative Acute Pain Management, People’s Medical Publishing House, 2014)
  4. Co-translator of Miller’s Anesthesiology (7th & 8th editions, Opioids section, 2017)

🏆SCIENCE AND TECHNOLOGY AWARDS:

Dr. Dai’s excellence in research and innovation has earned him several prestigious awards, including:

  • Second Prize of Hunan Natural Science Award (2019)
  • Third “Light of Spirit” Excellent Youth Research Fund – Second Prize
  • Award-winning fund for Young and Middle-aged Excellent Paper Competition at the Chinese Anesthesia Annual Meeting

🔮LEGACY AND FUTURE CONTRIBUTIONS:

As a pioneering figure in anesthesiology, Dr. Dai continues to shape the future of perioperative medicine, critical care, and pain management. His leadership in cutting-edge research, education, and healthcare innovation ensures his lasting impact in the field. Through mentorship and research, he remains dedicated to improving patient outcomes and advancing medical science, setting a benchmark for future anesthesiologists worldwide.

🌟CONCLUSION:

Prof. Dr. Ru-Ping Dai is a distinguished anesthesiologist and researcher at the Second Xiangya Hospital, Central South University, China. As the Director of the Department of Anesthesiology, he has significantly advanced perioperative medicine, focusing on neuroimmune interactions and organ protection. His notable work includes elucidating the roles of brain-derived neurotrophic factor (BDNF) and its precursor, pro-BDNF, in mood disorders, offering new perspectives on neuroimmune crosstalk. Prof. Dai’s dedication to integrating clinical practice with research has enhanced patient care and contributed to the global medical community’s understanding of anesthesiology and neuroscience.

TOP NOTABLE PUBLICATIONS

Brain derived neurotrophic factor (BDNF) contributes to the pain hypersensitivity following surgical incision in the rats

Authors: CQ Li, JM Xu, D Liu, JY Zhang, RP Dai
Journal: Molecular Pain
Year: 2008

Local translation and retrograde axonal transport of CREB regulates IL-6-induced nociceptive plasticity

Authors: OK Melemedjian, DV Tillu, JK Moy, MN Asiedu, EK Mandell, S Ghosh, …
Journal: Molecular Pain
Year: 2014

Early-life social isolation-induced depressive-like behavior in rats results in microglial activation and neuronal histone methylation that are mitigated by minocycline

Authors: HT Wang, FL Huang, ZL Hu, WJ Zhang, XQ Qiao, YQ Huang, RP Dai, F Li, …
Journal: Neurotoxicity Research
Year: 2017

Histone 2B (H2B) expression is confined to a proper NAD+/NADH redox status

Authors: RP Dai, FX Yu, SR Goh, HW Chng, YL Tan, JL Fu, L Zheng, Y Luo
Journal: Journal of Biological Chemistry
Year: 2008

Effects of down-regulation of microRNA-23a on TNF-α-induced endothelial cell apoptosis through caspase-dependent pathways

Authors: W Ruan, J Xu, S Li, L Yuan, R Dai
Journal: Cardiovascular Research
Year: 2012

Development of anxiety-like behavior via hippocampal IGF-2 signaling in the offspring of parental morphine exposure: effect of enriched environment

Authors: CQ Li, YW Luo, FF Bi, TT Cui, L Song, WY Cao, JY Zhang, F Li, JM Xu, …
Journal: Neuropsychopharmacology
Year: 2014

Dexmedetomidine reduces the incidence of fentanyl-induced cough: a double-blind, randomized, and placebo-controlled study

Authors: L He, JM Xu, RP Dai
Journal: Upsala Journal of Medical Sciences
Year: 2012

Adipocyte fatty acid-binding protein promotes palmitate-induced mitochondrial dysfunction and apoptosis in macrophages

Authors: H Li, Y Xiao, L Tang, F Zhong, G Huang, JM Xu, AM Xu, RP Dai, ZG Zhou
Journal: Frontiers in Immunology
Year: 2018

Insulin-like growth factor 2 mitigates depressive behavior in a rat model of chronic stress

Authors: YW Luo, Y Xu, WY Cao, XL Zhong, J Duan, XQ Wang, ZL Hu, F Li, …
Journal: Neuropharmacology
Year: 2015

Biphasic activation of extracellular signal-regulated kinase in anterior cingulate cortex distinctly regulates the development of pain-related anxiety and mechanical …

Authors: RP Dai, CQ Li, JW Zhang, F Li, XD Shi, JY Zhang, XF Zhou
Journal: Anesthesiology
Year: 2011

Yingqiang Du | Myocardial Infarction | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Dr. Yingqiang Du | Myocardial Infarction | Best Researcher Award

Dr. Yingqiang Du, Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University; Suzhou Municipal Hospital; Gusu School, Nanjing Medical University, China

Dr. Yingqiang Du is a renowned cardiology researcher at The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, and Gusu School, Nanjing Medical University, China. His research focuses on myocardial infarction and ischemic heart disease, exploring inflammation, fibrosis, metabolic remodeling, and novel therapeutic strategies. As the first or corresponding author of multiple high-impact publications, he has significantly contributed to cardiovascular medicine. His work bridges basic and clinical research, influencing treatment advancements and patient care. With ongoing projects funded by prestigious grants, Dr. Du continues to drive innovation in cardiology, shaping the future of cardiovascular health research.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

📚 EARLY ACADEMIC PURSUITS:

Dr. Yingqiang Du began his academic journey with a strong foundation in medical sciences, focusing on cardiology and cardiovascular research. His early education provided him with a deep understanding of human physiology, pathology, and the complexities of ischemic heart disease. With a keen interest in myocardial infarction and its underlying mechanisms, he pursued specialized training and research, laying the groundwork for his future contributions to the field.

🏥 PROFESSIONAL ENDEAVORS:

Currently, Dr. Du is affiliated with The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, and Gusu School, Nanjing Medical University. As a researcher and academic professional, he has taken on significant responsibilities in both clinical and experimental cardiology. His work bridges the gap between theoretical research and practical applications, ensuring that scientific findings translate into improved patient care.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON MYOCARDIAL INFARCTION:

Dr. Du’s research primarily centers on myocardial infarction and ischemic heart disease. His studies delve into various aspects, including:

  • The role of inflammation and fibrosis in cardiovascular conditions.
  • The impact of environmental factors, such as micro(nano)plastics, on heart disease.
  • Novel therapeutic approaches involving bioactive compounds like resveratrol and muscone.
  • The involvement of metabolic remodeling and inflammasome activation in aging cells. His extensive work provides crucial insights into the prevention, diagnosis, and treatment of cardiac disorders.

🌟 IMPACT AND INFLUENCE:

Dr. Du’s research has had a profound impact on the field of cardiology. His studies have contributed to a better understanding of the molecular mechanisms of myocardial infarction and fibrosis, paving the way for new treatment modalities. His findings have influenced clinical practices and have been referenced in various medical and scientific discussions worldwide.

📖 ACADEMIC CITES:

As an established researcher, Dr. Du has authored multiple high-impact publications in reputed journals, including:

  • Journal of Hazardous Materials
  • Clinical and Translational Medicine
  • Experimental and Therapeutic Medicine
  • Bioengineered
  • American Journal of Translational Research These publications, where he serves as either the first or corresponding author, reflect his credibility and expertise in the field. His work has been widely cited by peers, demonstrating its relevance and significance.

🏆 LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Du’s contributions to cardiology are paving the way for future breakthroughs in cardiovascular medicine. His research findings are not only enhancing current medical knowledge but also inspiring upcoming researchers to explore novel therapeutic strategies. Moving forward, his work is expected to contribute significantly to:

  • The development of innovative drug treatments for myocardial infarction.
  • The formulation of preventive measures against ischemic heart disease.
  • The exploration of new molecular pathways for better cardiovascular health. His ongoing commitment to research excellence ensures that his legacy will continue to shape the future of cardiology.

🌍CONCLUSION:

Dr. Yingqiang Du is a distinguished researcher whose groundbreaking contributions to cardiology have significantly advanced the understanding of myocardial infarction and ischemic heart disease. His extensive studies on inflammation, fibrosis, and metabolic remodeling have influenced both clinical practices and future research directions. With multiple high-impact publications and ongoing projects, his work continues to shape modern cardiovascular medicine.

TOP NOTABLE PUBLICATION

Title:  Exposure to polyethylene terephthalate micro(nano)plastics exacerbates inflammation and fibrosis after myocardial infarction by reprogramming the gut and lung microbiota and metabolome

Authors: X., Gu, Xin, Z., Zhang, Zhixuan, L., Zhao, Lin, … X., Wang, Xiaoyan, Y., Du, Yingqiang

Journal:  Journal of Hazardous Materials

Year: 2025